Pfizer, Astellas obtain FDA OK for Xtandi
Xtandi is the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer.IQVIA report analyzes drug shortages in the U.S.
Over the past five-and-a-half years, an average of more than 25 new molecule shortages have occurred annually, with 160 in total added through June of 2023 and only 51 resolved.